This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical-devices: Archive
CVS Expands Its Nationwide Care Network With Rite Aid Acquisition
by Moumi Mondal
CVS Pharmacy completes the Rite Aid deal, adding 63 stores, 626 pharmacies and nine million patients to its national care network.
UNHNegative Net Change CAHPositive Net Change CVSNegative Net Change
medical medical-devices
Is AMLX Stock a Solid Choice Right Now?
by Zacks Equity Research
Amylyx has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
AMLXPositive Net Change
medical-devices
Reasons to Add HealthEquity Stock to Your Portfolio for Now
by Zacks Equity Research
HQY's strong Q2, expanding HSAs and AI-driven efficiencies highlight its growth momentum despite data security risks.
MASINegative Net Change MMSINegative Net Change WSTNegative Net Change HQYPositive Net Change
medical medical-devices
J&J Bets on MedTech Growth With Orthopaedics Unit Spin-Off Plan
by Kinjel Shah
J&J's surprise plan to spin off its Orthopaedics unit as DePuy Synthes is aimed at sharpening MedTech focus and boosting growth margins.
JNJPositive Net Change MDTNegative Net Change SYKPositive Net Change KVUENegative Net Change
medical medical-devices pharmaceuticals
Hims & Hers Elevates Technology-Driven Healthcare Accessibility
by Debanjana Dey
HIMS boosts AI-led care with new technology chief, hormone therapies and a global push via its ZAVA acquisition.
TDOCNegative Net Change HIMSNegative Net Change TEMPositive Net Change
medical medical-devices
Should You Add CVS Health Stock to Your Portfolio Before Q3 Earnings?
by Moumi Mondal
CVS Health prepares Q3 results, with pharmacy performance and Aetna's progress in focus for investors.
UNHNegative Net Change CVSNegative Net Change ELVNegative Net Change
earnings-preview medical medical-devices
Merit Medical Expands GI Portfolio With $22M C2 CryoBalloon Acquisition
by Zacks Equity Research
MMSI is set to acquire C2 CryoBalloon from Pentax for $22M, strengthening its GI portfolio. Despite near-term dilution, the deal positions Merit for long-term growth in gastroenterology.
MASINegative Net Change MMSINegative Net Change DRIOPositive Net Change NDRANegative Net Change
medical medical-devices
GEHC Stock Up Following New Launch to Streamline Perinatal Workflow
by Zacks Equity Research
GE HealthCare unveils CareIntellect for Perinatal, a SaaS tool aimed at improving maternal and fetal care delivery.
RMDNegative Net Change HCAPositive Net Change GEHCPositive Net Change SOLVPositive Net Change
medical medical-devices
Reasons to Hold Veeva Systems Stock in Your Portfolio for Now
by Zacks Equity Research
VEEV's strong Q2, expanding AI strategy and major life sciences partnerships fuel growth despite rising costs.
MASINegative Net Change MMSINegative Net Change WSTNegative Net Change VEEVNegative Net Change
medical medical-devices
Abbott's Q3 Earnings Meet Estimates, Revenues Up Y/Y, Stock Climbs
by Zacks Equity Research
ABT's Q3 earnings meet expectations as revenues climb 6.9% year over year, driven by double-digit gains in Medical Devices.
ABTNegative Net Change PODDPositive Net Change PAHCNegative Net Change VCYTPositive Net Change
earnings medical medical-devices
Brookfield Infrastructure Partners (BIP)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
BIPNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Labcorp Gears Up to Report Q3 Earnings: What's in Store for the Stock?
by Zacks Equity Research
LH is poised for Q3 growth, with revenue and EPS estimates pointing higher as diagnostics and biopharma units deliver strong performances.
LHPositive Net Change IDXXPositive Net Change ANIPNegative Net Change EXASPositive Net Change
earnings medical medical-devices
Can Ion Emerge as ISRG's Vehicle to Tap Ambulatory Care Growth?
by Indrajit Bandyopadhyay
Intuitive Surgical's Ion platform gains traction in ambulatory centers, driving 52% growth as outpatient lung diagnostics accelerate.
BSXNegative Net Change BDXNegative Net Change ISRGPositive Net Change
medical medical-devices
Reasons to Retain West Pharmaceutical Stock in Your Portfolio for Now
by Zacks Equity Research
WST's growth prospects remain strong, fueled by GLP-1 demand and high-value products, though tariffs and execution risks weigh on margins.
CAHPositive Net Change MASINegative Net Change MMSINegative Net Change WSTNegative Net Change
medical medical-devices
NVDA & PLTR Driving AI in Health: Top Health IT Stocks for Q3 Earnings
by Urmimala Biswas
NVDA and PLTR drive AI integration across healthcare, fueling optimism for Omnicell and Tempus AI's Q3 performance.
NVDAPositive Net Change OMCLNegative Net Change ORCLPositive Net Change PLTRNegative Net Change TEMPositive Net Change
artificial-intelligence earnings medical medical-devices robotics smart-health tech-stocks
Hims & Hers Gains 3.8% in 3 Months: Time to Hold the Stock or Sell?
by Debanjana Dey
HIMS expands into men's health and hormones, but rising costs and regulatory hurdles threaten its momentum.
TDOCNegative Net Change AMWLNegative Net Change HIMSNegative Net Change
medical medical-devices
STXS Partners With CardioFocus to Boost Robotic Pulsed Field Ablation
by Zacks Equity Research
Stereotaxis partners with CardioFocus to commercialize the first robotic Pulsed Field Ablation system, aiming to revolutionize cardiac arrhythmia treatment.
MASINegative Net Change MMSINegative Net Change STXSNo Net Change WSTNegative Net Change
medical medical-devices
Here's How Quest Diagnostics Is Placed Ahead of Q3 Earnings
by Zacks Equity Research
DGX is poised for solid Q3 2025 results, backed by strong DIS growth, strategic M&A and robust test demand across key health segments.
DGXPositive Net Change IDXXPositive Net Change ANIPNegative Net Change EXASPositive Net Change
earnings medical medical-devices
HOLX's Enhanced Fibroid Treatment Portfolio Powers GYN Surgical Growth
by Moumi Mondal
Hologic's GYN Surgical segment gains momentum internationally as expanded fibroid treatments support growth.
JNJPositive Net Change MDTNegative Net Change HOLXPositive Net Change
medical medical-devices
Can ISRG Continue Its Strong Growth Amid Tariff & Rare Earth Woes?
by Indrajit Bandyopadhyay
ISRG's growth momentum faces pressure as tariffs and China's rare earth export curbs threaten margins and supply stability.
SYKPositive Net Change ISRGPositive Net Change GMEDPositive Net Change
medical medical-devices
New Strong Sell Stocks for Oct. 14th
by Zacks Equity Research
AR, BTCS and ATOS have been added to the Zacks Rank #5 (Strong Sell) List on October 14, 2025.
ATOSNegative Net Change ARNegative Net Change BTCSNegative Net Change
finance medical-devices oil-energy
BD Stock Down Despite Making Progress in the Treatment of PAD Lesions
by Zacks Equity Research
BDX advances PAD care with first patient enrolled in the XTRACT Registry using its dual-action Rotarex system.
BDXNegative Net Change RMDNegative Net Change MASINegative Net Change SOLVPositive Net Change
medical medical-devices
INSP Shares Down Despite Strong Clinical Data From Inspire V Trials
by Zacks Equity Research
Inspire Medical's Inspire V system shows strong safety, faster surgeries, and higher patient adherence in new trials.
MASINegative Net Change MMSINegative Net Change WSTNegative Net Change INSPNegative Net Change
medical medical-devices
CVS' Aetna Wins Big on 2026 MA Star Ratings: How to Play the Stock?
by Moumi Mondal
CVS' Aetna shines in 2026 Medicare Star Ratings, with more than 81% of members in four-star plans, fueling a 73.5% YTD stock surge and strong investor momentum.
UNHNegative Net Change HUMNegative Net Change CVSNegative Net Change
medical medical-devices
Pulse Biosciences Unveils Promising First-in-Human Data for nPulse
by Zacks Equity Research
PLSE unveils strong first-in-human data for its nPulse Cardiac Surgical System, showcasing safety, speed, and durable AF treatment potential.
EWPositive Net Change MASINegative Net Change PLSENegative Net Change NDRANegative Net Change
medical medical-devices